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Abstract 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder, which is characterized by the accumulation of amyloid 
plaques and neurofibrillary tangles in specific regions of the brain, accompanied by impairment of the neurons, and progressive 
deterioration of cognition and memory of affected individuals. Although the cause and progression of AD are still not well 
understood, the amyloid hypothesis is dominant and widely accepted. According to this hypothesis, an increased deposition of 
amyloid-β peptide (Aβ) in the brain is the main cause of the AD’s onset and progression. There is increasing body of evidence 
that blood-brain barrier (BBB) dysfunction plays an important role in the development of AD, and may even precede neuron 
degeneration in AD brain. In the early stage of AD, microvasculature deficiencies, inflammatory reactions, surrounding the 
cerebral vasculature and endothelial dysfunctions are commonly observed. Continuous neurovascular degeneration and 
accumulation of Aβ on blood vessels resulting in cerebral amyloid angiopathy is associated with further progression of the 
disease and cognitive decline. However, little is known about molecular mechanisms that underlie Aβ induced damage of 
neurovascular cells. In this regards, this review is aimed to address how Aβ impacts the cerebral endothelium.  Understanding the 
cellular pathways triggered by Aβ leading to alterations in cerebral endothelial cells structure and functions would provide 
insights into the mechanism of BBB dysfunction and inflammatory processes in Alzheimer’s, and may offer new approaches for 
prevention and treatment strategies for AD. 
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Introduction 
Alzheimer’s disease is a chronic 
neurodegenerative disorder, which affects 
approximately 10% of the population at age 65 and 40%  
 
of people over the age 80. AD is characterized by the 
accumulation of amyloid plaques and neurofibrillary 
tangles accompanied by impairment of the neurons in 
specific regions of the brain. In particular, large neurons 
in the neurocortex, the entorhinal area, hippocampus, 
amygdale, nucleus basalis, anterior thalamus, and 
several brain stem monoaminergic nuclei are affected. 
In damaged regions, the neurons exhibit multiple 
abnormalities of cell structure and function, reduction in 
the level of synaptic proteins, and, finally, they die.
1
 The 
neuronal loss in AD brains is accompanied by 
progressive deterioration of cognition and memory of 
affected individuals.  
Although the cause and progression of AD are 
still not well understood, the amyloid hypothesis is 
dominant and widely accepted.
2
 According to this 
hypothesis, an increased deposition of amyloid-β 
peptide, the main constituent of senile plagues, is the 
main cause of neuronal dysfunction and death in AD.  
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The rest of the disease process, including formation of 
neurofibrillary tangles containing tau protein, is 
proposed to result from an imbalance between Aβ 
production and Aβ clearance. Aβ is derived from 
amyloidogenic cleavage of membrane bound amyloid 
precursor protein (APP) by - and -secretase.3 
Amyloidogenic processing of the APP leads to the 
production of Aβ peptides of different length, of which 
the Aβ1-40 is the major species and the Aβ1-42 is the most 
fibrillogenic and predominant component in AD 
plaques.
4
 
There is major evidence which supports 
Amyloid Cascade Hypothesis. The first comes from the 
link between AD and Down’s Syndrome.  The APP 
gene is localized on chromosome 21, and people with 
Down Syndrome (trisomy 21) who, thus, have an extra 
gene copy almost invariably develop AD-like 
neuropathology by the age of 40. Secondly, inherited 
mutations in the APP and presenilin genes (presenilin 
constitutes the catalytic site of the γ-secretase) cause 
early and aggressive forms of AD. And thirdly, 
transgenic mice with mutant form of human APP 
develop amyloid fibrillar plaques and Alzhemer’s like 
brain pathology.
2
 
Recent reports have suggested that the soluble 
oligomeric form of the peptide is the most toxic and 
responsible for the disruption of synaptic plasticity, 
neuronal death and decline of cognitive function.
5,6
 
Although precise mechanism of Aβ oligomers 
neurotoxic effects remains unclear, in-vivo and in-vitro 
studies have demonstrated that Aβ oligomers:  a) induce 
apoptosis; b) initiate oxidative stress and free-radical 
degeneration in neuronal cells; c) disrupt calcium 
homeostasis and long-term potentiation; d) cause 
neurodegeneration by forming large, voltage 
independent, and nonselective ion channels.
7,8
 
However, for the most cases of late-onset 
sporadic non-inherited AD (~95%), the reasons of 
increased Aβ accumulation in brains remain unknown. 
In this regard, current theories imply that AD is mainly 
caused by vascular risk factors, and that vascular 
derived pathology is responsible for initiation and/or 
progression of AD.
9-11
 Recent studies provided 
significant data supporting the notion that the 
pathophysiology of blood brain barrier (BBB) and 
imbalanced interaction between cerebral endothelial 
cells (CECs), glial cells and neurons may trigger the 
progressive destruction of cortical neurons in AD.
10,12-21
 
 
1. Blood-Brain Barrier Disorder in AD 
The homeostasis of the Central Nervous 
System (CNS) is maintained by the BBB, which 
separates the brain from the circulating bloodstream. 
The BBB is formed by a complex cellular system 
consisting of CECs, astrocytes, pericytes, perivascular 
macrophages, and a basement membrane (Fig 1.).
22
  
 
Fig. 1. The Blood-Brain Barrier. 
 
CECs layer is a major component of the BBB 
which is comprised of high-density cells connected by 
tight junctions. CECs have a little number of endothelial 
pores, rich in mitochondria, and have a very low content 
of the pinocytic vesicles. The biomechanical properties 
of the CECs are critical to the regulation of many 
cellular functions, such as adhesion, signaling and 
morphology, and play a vital role for the maintenance of 
the BBB permeability, and brain parenchyma 
homeostasis.  Astrocytes, the most frequent cells of the 
brain, also play an important role in maintaining BBB 
function. Their end feet tightly connected to the CECs 
influencing cerebrovascular tone and the barrier 
properties of endothelium.
20
 Pericytes are characterized 
as contractile cells that surround the brain capillaries. 
Pericytes play an important role in maintaining the 
stability of microvessels and modulation of Cerebral 
Blood Flow (CBF). Sporadic microglia can also be 
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found in the surrounding pericapillary area in normal 
brain.
16
 
There is increasing body of evidence that BBB 
dysfunction plays an important role in the development 
and progression of AD.
14-17,23,24
 Vascular disorders like 
atherosclerosis, ischemia, hypertension, and stroke are 
among the risk factors for AD.
18,20,21
 In the early stage 
of AD, microvasculature deficiencies, inflammatory 
reactions, surrounding the cerebral vasculature and 
endothelial dysfunctions are commonly observed.
25
 The 
increased number of perivascular macrophages and 
hypertrophy of astrocytes and microglia is commonly 
observed in AD brain sections.
26
 Numerous 
observations have indicated decreased cerebral blood 
flow, reduced total microvascular density, and low 
immunoreactivity of endothelial markers CD34 and 
CD3 in AD brains.
27-32
 Light and electron microscopy 
studies have demonstrated decreased mitochondrial and 
increased pinocytotic vesicles content, swelling and 
degeneration of endothelial cells.
33,34
  
In vitro, amyloid beta peptide has been shown 
to induce significant dysfunctions in the CECs. 
Specifically, Aβ suppressed CECs proliferation and 
migration, affected tube formation in the human brain 
endothelial cells (HBEC), induced endothelial 
autophagy through the dissociation of ERK and AKT 
signaling and intracellular regulation of class 3 
phosphatidylinositol
 
3-kinase.
35,36
 Physiological 
concentrations of soluble Aβ (10-9 - 10-6 M) induced 
dose-dependent reduction of NO production, decreased 
sensitivity of neurovasculature to an endothelium 
dependent vasodilator acetylcholine, increased cellular 
calcium level, initiated albumin transfer across EC 
monolayer and impaired EC glucose uptake.
24,37-39
 
Higher concentrations of Aβ have been demonstrated to 
induce mitochondria dysfunction, nuclear chromatin 
condensation, DNA fragmentation, and significant 
cerebral endothelial cell death.
37,38,40
 Continuous 
neurovascular degeneration and accumulation of Aβ on 
blood vessels resulting in cerebral amyloid angiopathy 
is associated with further progression of the disease and 
cognitive decline
14,15,17,41,42
 
 
2. Oxidative Stress, Inflammation, and Downstream 
Cell Signaling Pathways in AD 
There is increasing evidence that oxidative 
stress is a main mechanism leading to cerebrovascular 
dysfunction in AD. Several studies of transgenic mice 
over expressing APP have demonstrated oxidative 
damage of CECs, up regulation of superoxide dismutase 
(SOD) around brain micro vessels, and significant 
impairment of the cerebrovascular functions.
43-45
 At the 
same time, endothelial dysfunctions were not observed 
in mice over expressing both APP and SOD-1 or in a 
case when SOD was directly applied to the cerebral 
cortex of the APP mice.
44
 In vitro, treatment of CECs 
with Aβ increased free radical production and this effect 
was attenuated by free radical scavengers.
43,46
 
The oxidative stress initiates a cascade of redox 
reactions which trigger apoptosis.  Several studies have 
indicated that Aβ -induced CECs death had an apoptotic 
nature and was a result of the mitochondria dysfunction, 
activation of a caspase upstream, and proapoptotic 
proteins release
38,40,47,48
 Aβ induced oxidative stress also 
triggers downstream kinase cascades leading to 
neurovascular inflammation.
49,50
 Study of the 
microvessels isolated from the AD patients brains have 
revealed significantly higher levels of interleukin-1β 
(IL-1β), IL-6, tumor necrosis factor α (TNF-α),  
microvessel-associated monocyte chemoattractant 
protein (MCP-1) and IL-1βs.49 In-vitro, the exposure of 
HBEC to Aβ induced induction of CD40 (a member of 
TNF receptor family), secretion of interferon-γ (IFN-γ) 
and IL-1β, expression of of IFN-γ receptor (IFN-γR), 
and triggered inflammatory genes MCP-1, GRO, IL-1β 
and IL-6 expression via JNK-AP1 signaling pathway.
50-
52
 
Aβ-induced oxidative stress in cerebral 
epithelium is associated with overproduction of reactive 
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oxygen species (ROS).
20,53-55
 ROS can be generated by 
several enzymatic systems, but there is evidence that 
superoxide-producing enzyme NADPH oxidase A is 
major source of ROS in the brain blood vessels.
54-56
 In a 
model of AD, inhibition of NADPH oxidase has been 
found to abrogate Aβ induced ROS production and 
alteration of cerebrovascular functions.
54
 APP 
transgenic mice lacking the NADPH oxidase subunits 
gp91
phox
 or Nox2 did not develop oxidative stress, 
cerebrovascular dysfunction, and behavioral deficits.
54,55
 
Recent studies have indicated that the receptor 
for advanced glycation endproducts (RAGE) is a 
binding site for Aβ.57-62 RAGE is a multiligand cell 
surface receptor which is normally expressed in brain 
endothelium and, at low levels, in microglia and 
neurons.
15,60,61
 However, in AD brains RAGE 
expression is increased by several-fold in cerebral 
endothelial cells, astrocytes, microglia, and neurons.
60,61
 
ROS have been reported to be generated by NADPH 
oxidase through the RAGE in endothelial cells.
62,63
  
Inhibition studies have indicated that anti-RAGE IgG 
significantly suppressed oxidative stress and 
inflammation induced by Aβ in vascular cells and 
neurons.
57
 RAGE binding to Aβ has been also 
demonstrated to regulate Aβ transport across BBB, 
upregulate pro-inflammatory cytokines and adhesion 
molecules in CECs, and contribute to the transport of 
Aβ from the cell surface into the intracellular space in 
cortical neurons
61,64,65
 
Aβ-induced cytotoxic effects are also 
associated with the activation of MAPK/ERK1/2 
cascade and that activated ERKs (extracellular-signal-
regulated kinases) is the central target of RAGE.
62,66-72
 
The ERKs are widely expressed protein kinases, part of 
a signal transduction system, through which 
extracellular
 
stimuli are transduced.  Activation of the 
ERKs occurs in response
 
to growth factor stimulation, 
cytokines, virus infection, transforming agents, 
carcinogens, and after the activation of high-affinity
 
IgG 
receptors.
71
 ERKs have been implicated in diverse 
cellular responses such as mitogenesis, differentiation, 
inflammation and cytotoxicity, and the overproduction 
of this enzyme is involved in many neurodegenerative 
diseases, including AD.
67,73,74
 Thus, NADPH oxidase, 
ERKs and RAGE have been suggested to be important 
therapeutic targets in AD. 
 
3. Permeability of Cerebral Endothelium in AD 
In the AD, an increased deposition of Aβ in the 
cerebral vasculature has been found to correlate with 
accumulation of monocytes in the vessel walls and of 
activated microglia cells in the adjacent parenchyma.
75-
77
 Since peripheral monocytes can migrate across the 
BBB and differentiate into microglia,
78
 which, in turn, 
drives the disease development towards exacerbation of 
the oxidative and inflammatory conditions characteristic 
of the AD brain, several research groups have attempted 
to demonstrate the direct effect of Aβ on endothelial 
functions leading to enhanced transmigration of 
monocytes.   
 In-vitro studies have shown that soluble Aβ 
interactions with RAGE and platelet-endothelial cell 
adhesion molecule-1 (PECAM-1) at the apical surface 
and basolateral sides of monolayer of brain endothelial 
cells increased transendothelial migration of monocytic 
cells.
79-81
 Based on the observation that the permeability 
of the monolayer toward dextran and inulin in the 
presence or absence of Aβ42 remained unaltered,
79
 it has 
been concluded that enhanced transmigration of 
monocytes induced by Aβ is not only due to nonspecific 
disruption of the barrier properties of the endothelial 
layer, but also is a consequence of Aβ induced 
expression of the chemokines and adhesion molecules. 
Since primary capture of the monocytes to endothelium 
and rolling are mediated by tethering on selectins and 
selectin ligands,
82-84
 the expression of adhesion 
molecules, mechanical properties of the membranes 
(fluidity, elasticity) and membrane-cytoskeleton 
interactions are critical for transmigration.
85-90
 Atomic 
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force microscopy and quantitative immunofluorescence 
microscopy studies have demonstrated that Aβ 
oligomers induced P- selectin expression, increased cell 
stiffness, decreased the apparent rupture force of 
selectin-ligand bonding due to dissociation of adhesion 
between the cytoskeleton and the bilayer membrane, 
and, thus, increased probability of adhesion. 
91
  
The presence of the tight junctions of high 
electrical resistance and close cell-cell contact are 
important biomechanical factors maintaining brain 
homeostasis and BBB impermeability. Tight junction is 
a complex of transmembrane proteins (occluding, 
claudins, junctional molecule-1) and submembrane 
molecules connected to actin network. In fact, the 
structure and functions of the tight junctions are 
strongly affected in the cerebrovascular cells of AD 
patients.
92
 In an animal model of AD, a cholesterol-
enriched diet down-regulated the expression of the 
occluding and ZO-1, which was strongly correlated with 
the elevated level of the BBB leakage.
93
 In vitro, 
treatment of primary rat CECs with Aβ1-42 for 3 days 
altered expression of occluding and claudin-1, caused 
relocation of plasma membrane subunits of claudin-5 
and ZO-2 to the cytoplasm. At the same time, the 
cytoplasmic ZO-1 and ZO-2 where evenly distributed 
along the plasma membrane at the points of the cell-cell 
contacts.
94
 Apolipoprotein E4 (apoE4), a major risk 
factor for AD, has been shown to be involved in tight 
junction alteration as well.
95
 It has been shown that mice 
deficient in apoE have expressed BBB leakage.  In vitro 
study has demonstrated that the barrier functions of tight 
junctions was impaired when the CECs were 
reconstituted with primary astrocytes from apoE4-
knock-in mice. In particular, the phosphorylation of 
occludin and the activation of protein kinase C (PKC)η 
in CECs were attenuated.  
These findings suggest that the effects of Aβ 
on actin and tight junction protein complexes, as well as 
vascular risk factors cause the alteration of endothelial 
layer integrity and contribute to the enhanced 
transmigration of monocytes across the BBB. Thus, 
studying the Aβ-mediated alterations in endothelial 
adhesion and BBB permeability would provide insights 
into the mechanism of BBB dysfunction and may 
provide information for developing new targeted drug 
delivery vehicles
96
 for the AD brain.   
 
Conclusion 
Chronic neurovascular dysfunctions and 
degeneration of endothelium are observed in the all 
stages of AD. Numerous in vivo and in vitro studies 
have demonstrated that vascular deposition of amyloid 
beta peptide induces oxidative stress in cerebral 
vasculature, triggers inflammatory processes and 
apoptosis, promotes expression of adhesion molecules, 
affects tight junctions, changes mechanical properties of 
the CECs membranes, and enhances transmigration of 
immune cells across BBB. Continuous degeneration of 
CECs impairs BBB permeability and leads to leakage of 
blood cells, plasma components and neurotoxic 
substances into the brain parenchyma. Breakdown of 
blood brain barrier functions drives the disease 
development towards exacerbation of the oxidative and 
inflammatory conditions characteristic of the AD brain 
and contributes to further progression of the disease. 
Understanding the precise molecular mechanisms 
underlying A-mediated oxidative stress in CECs, the 
effects of Aβ42 on the BBB adhesion and permeability 
should prove to provide new insights into the 
development of preventive and treatment strategies for 
AD. 
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Fig. 1. The Blood-Brain Barrier. (Adapted from Expert Reviews in Molecular Medicine, 2003 Cambridge 
University Press) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
